Endo begins Mersana's foray into antibody-drug conjugates with $270 million deal
This article was originally published in Scrip
Mersana Therapeutics announced a collaboration agreement with Endo Pharmaceuticals worth up to $270 million plus royalties, its first deal in antibody-drug conjugates (ADCs).
You may also be interested in...
During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.